Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk.

Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk.
复制标题

DOI:
10.1186/1471-2334-8-28
复制
发表时间:
2008-03-06
影响因子:
3.7
通讯作者:
Berner R
Berner R
中科院分区:
医学3区
文献类型:
--
作者:
Diepold M;Noellke P;Duffner U;Kontny U;Berner R

文献摘要

参考文献

被引文献

相似文献

化疗相关的中性粒细胞减少和发热患者通常住院,并接受经验性静脉注射广谱抗生素治疗。由于感染的非特异性临床和实验室体征,发热性中性粒细胞减少症患儿的脓毒症的早期诊断仍然很困难。我们的目的是分析IL-6和IL-8是否可以定义一组低风险败血症患者。进行了一项前瞻性研究,以评估IL-6,IL-8和C-反应蛋白血清水平的潜在价值,以预测严重的细菌感染或菌血症的发热性贫血儿童癌症化疗期间。使用的统计检验:Friedman检验、Wilcoxon检验、Kruskal-Wallis H检验、Mann-Whitney U检验和接受者操作特征。在发热开始时测量的细胞因子水平的分析表明,IL-6和IL-8是有用的,以确定一个可能的组的患者具有低风险的脓毒症。在预测菌血症或严重细菌感染时,IL-6是最佳预测因子,最佳IL-6临界值为42 pg/ml,显示出高灵敏度(90%)和特异性(85%)。这些发现可能对基于风险的抗菌治疗策略具有临床意义。
Patients with chemotherapy-related neutropenia and fever are usually hospitalized and treated on empirical intravenous broad-spectrum antibiotic regimens. Early diagnosis of sepsis in children with febrile neutropenia remains difficult due to non-specific clinical and laboratory signs of infection. We aimed to analyze whether IL-6 and IL-8 could define a group of patients at low risk of septicemia. A prospective study was performed to assess the potential value of IL-6, IL-8 and C-reactive protein serum levels to predict severe bacterial infection or bacteremia in febrile neutropenic children with cancer during chemotherapy. Statistical test used: Friedman test, Wilcoxon-Test, Kruskal-Wallis H test, Mann-Whitney U-Test and Receiver Operating Characteristics. The analysis of cytokine levels measured at the onset of fever indicated that IL-6 and IL-8 are useful to define a possible group of patients with low risk of sepsis. In predicting bacteremia or severe bacterial infection, IL-6 was the best predictor with the optimum IL-6 cut-off level of 42 pg/ml showing a high sensitivity (90%) and specificity (85%). These findings may have clinical implications for risk-based antimicrobial treatment strategies.
DOI: 10.1056/nejm199907293410501
发表时间: 1999-07-29
影响因子: 158.5
作者:
Freifeld, A;Marchigiani, D;Pizzo, PP
通讯作者: Pizzo, PP
DOI: 10.1056/nejm199907293410502
发表时间: 1999-07-29
影响因子: 158.5
作者:
Kern, WV;Cometta, A;Gaya, H
通讯作者: Gaya, H
DOI: 10.1016/s0001-2998(78)80014-2
发表时间: 1978-01-01
影响因子: 4.9
作者:
METZ, CE
通讯作者: METZ, CE
DOI: 10.1097/00006454-199209000-00007
发表时间: 1992-09-01
影响因子: 3.6
作者:
KATZ, JA;MUSTAFA, MM;BUCHANAN, GR
通讯作者: BUCHANAN, GR
DOI: 10.1203/00006450-199810000-00002
发表时间: 1998-10-01
期刊: PEDIATRIC RESEARCH
影响因子: 3.6
作者:
Berner, R;Niemeyer, CM;Brandis, M
通讯作者: Brandis, M